Iphise Ds8201a

Kākau pōkole:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Huahana kikoʻipiop

Nā Kūlana Huakaʻi

  • ʻO ka discription huahana DS - 8201A,ʻike pū kekahi me he trastuzumab deruxtecan (t - DXD) E hui pū me kāna HER2 - E nānā i ka Antibonital Antibody Hāʻawi ka lāʻau i ka chemotherapy pololei i ka cancer cell e hōʻike ana i kāna hana e hōʻike ana i keʻano o ka hoʻopauʻana i nā hana maʻamau.
    • KahuaPa:
      Piook
    • Meaʻaʻole .:
      015200.02
    • Nā'āpana helu:
      200ul, 2mg / ml
    • Tissue:
      N / a
    • Nāʻano:
      N / a
    • Nā Kūlana Kūʻai a me nā halihali:
      Kūʻai ma - 70 ° C. Ua hāʻawiʻia ka hau maloʻo.

  • MAUI:
  • Akahi:
  • Palapala Koho'ōlelo